Swiss clinical stage biopharmaceutical company AC Immune has discovered new antibodies against two targets, Alpha-synuclein and TDP-43, in the pathogenesis of neurodegenerative diseases.

While Alpha-synuclein is a long-established target for Parkinson's disease and other Lewy body diseases, TDP-43 is a newly identified target that is important for neuro-orphan indications such as Frontotemporal Lobar Degeneration (FTLD-TDP).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, both targets play a major role in other significant neurodegenerative indications such as Alzheimer's disease, beyond the established hallmarks of amyloid beta-peptide (Abeta) and Tau.

AC Immune chief executive officer Andrea Pfeifer said: “We are very pleased to move these next-generation antibodies into our discovery pipeline.

“They have significant potential for addressing the underlying pathology of a range of unmet indications, and reinforce our belief that precision medicine is critical to delivering effective treatments in Alzheimer's disease and other neurodegenerative diseases.

See Also:

"We are executing a clear strategy around three pillars: Alzheimer's disease, other significant neurodegenerative diseases and neuro-orphan indications, and diagnostics."

“We are executing a clear strategy around three pillars: Alzheimer's disease, other significant neurodegenerative diseases and neuro-orphan indications, and diagnostics.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company used its latest SupraAntigen platform to discover the new antibodies.

AC Immune chief scientific officer Dr Andreas Muhs said: “Many neurodegenerative diseases share their mode-of-action and targets, which provides opportunities for synergistic development of product candidates.

“Our common scientific approach to proteinopathies, complemented with proprietary diagnostics, consistently and rapidly delivers new high-quality treatments for precision medicine in neurodegenerative diseases.

“These two latest antibody programmes have unique binding properties to only the pathological forms of alpha-synuclein and TDP-43, and we are encouraged by the observations of expert groups on their potential attributes as novel therapeutics.”